SCHEDULE 13G/A: Invus Entities and Raymond Debbane Disclose Significant Stake in Solid Biosciences Inc.
Beneficial Ownership Report
Multiple Invus-affiliated entities and Raymond Debbane have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 9.6% in Solid Biosciences Inc.'s common stock as of March 31, 2025.
Summary
- Invus Public Equities, L.P. directly holds 6,402,653 shares of Solid Biosciences Inc. common stock, representing 8.3% of the class.
- Avicenna Life Sci Master Fund LP directly holds 1,013,252 shares, representing 1.3% of the class.
- Raymond Debbane, through his control over Siren, L.L.C. and Ulys, L.L.C., is deemed to beneficially own an aggregate of 7,415,905 shares, which constitutes 9.6% of the outstanding common stock.
- The beneficial ownership percentages are calculated based on 77,492,959 shares outstanding as of March 3, 2025, as reported in Solid Biosciences Inc.'s Annual Report on Form 10-K.
- The filing states that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or prospects.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of significant beneficial ownership in a publicly traded biotechnology company. It indicates a substantial, passive investment by a group of related investment entities and an individual, which is common for institutional investors in the biotech sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional and individual ownership, which can influence market perception and potential future corporate actions, though the filing states the purpose is not to change or influence control.
Key Dates
| Date | Description |
|---|---|
| 2025-03-03 | Date as of which the number of outstanding shares (77,492,959) was reported in Solid Biosciences Inc.'s Form 10-K. |
| 2025-03-31 | Date of event which requires the filing of this statement, reflecting the beneficial ownership. |
| 2025-04-17 | Date the Schedule 13G Amendment No. 4 was signed and filed. |
Keywords
Solid Biosciences Inc., Invus Public Equities, Avicenna Life Sci Master Fund, Raymond Debbane, Beneficial Ownership, Schedule 13G, Common Stock, Biotechnology, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.